Pre-Clinical Safety of Stempeucel® – Safety & Efficiency Proven

Stempeucel® Features

  • Multipotent (multilineage differentiation – adipogenesis, osteogenesis, chondrogenesis)
  • Immunosuppressive (inhibition of lymphocyte proliferation, no short-term or long-term effects on lymphocyte profile)
  • Effective engraftment to the defect site without localizing to other organs

Pre-Clinical Safety

  • No side effect observed.
  • Non-toxic, non-teratogenic and non-tumorigenic for single and multiple administration of Stempeucel® at various doses through intravenous or intramuscular routes.
  • No prenatal toxicity observed in pregnant model.
  • No tumour formation observed in severe combined immunodeficient model.
  • A death occurs one day after high dose intravenous administration of Stempeucel®. However, no treatment-related gross pathological and histopathological changes were observed. This proves that the death is unrelated to the product.

Overview of Safety in Non-Atherosclerotic Critical Limb Ischemia

  1. Single and multiple administration of Stempeucel® is safe.
  2. Stempeucel® does not elicit systemic or localized toxic effect.
  3. It is non-tumorigenic and non-teratogenic in nature.
Download Full Articles
Shopping Basket